Monitoring of low molecular weight heparin in pregnancy.
Shiach
Caroline R
CR
Department of Clinical Haematology, Manchester Royal Infirmary, UK. cshiach@labmed.cmht.nwest.nhs.uk
D000328:Adult; D000925:Anticoagulants / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001780:Blood Coagulation Tests; D004341:Drug Evaluation; D065427:Factor Xa Inhibitors; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D010314:Partial Thromboplastin Time; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000517:prevention & control*; D011295:Prenatal Care / Q000379:methods; D011655:Pulmonary Embolism / Q000517:prevention & control*; D019851:Thrombophilia / Q000097:blood / Q000188:drug therapy*; D020246:Venous Thrombosis / Q000517:prevention & control*
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin